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Although it is well known that platelet-derived growth factor
(PDGF) causes mesangial cell proliferation (presumably
contributing to progression of glomerular disease), targeted
inhibition of the PDGF receptor system has shown only
limited efficacy against glomerular diseases. To examine
whether this discrepancy is due to the involvement of other
pathways, we used phosphorylated receptor tyrosine kinase
arrays and found that RON (recepteur d’origine nantais) was
phosphorylated while the PDGF receptor was
dephosphorylated (thus inactive) in human mesangial cells
(HMCs) at the time of cell cycle entry. Further, RON remained
active during steady-state growth. Activation of RON was
independent of its canonical ligand, macrophage-stimulating
protein, but was mediated by transactivation from the PDGF-
engaged PDGF receptor. Following stimulation with PDGF we
found that the two receptors physically interacted.
Knockdown of RON by siRNA increased the number of
apoptotic cells without affecting the rate of DNA synthesis,
suggesting that RON has anti-apoptotic functions.
Immunohistochemical analysis found phosphorylated RON in
glomerular lesions of patients with IgA nephropathy but not
those with minimal change nephrotic syndrome, a disease
not associated with mesangial proliferation. These results
suggest that RON is involved in mesangial cell proliferation
under both physiological and pathological conditions, and
may be a relevant target for therapeutic intervention.
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Mesangial cell proliferation plays an important role in the
progression of glomerular diseases, including IgA nephro-
pathy, a major cause of end-stage renal failure. Elucidation of
the mechanisms of mesangial cell proliferation may contribute
to the development of effective treatment strategies for
glomerular diseases. However, molecular basis of mesangial
cell proliferation has not been fully understood, although
earlier studies have indicated the involvement of growth
factors especially platelet-derived growth factor (PDGF).1,2
PDGF is a pleiotropic growth factor that was originally
isolated from human platelet-rich plasma. PDGF consists of
five dimeric isoforms (AA, AB, BB, CC, and DD) and binds
to three structurally related receptors (a/a, a/b, and b/b),
which transduce mitogenic signals through their tyrosine
kinase domains to downstream effector kinases such as ERK
and AKT.1–3 As PDGF is synthesized by resident renal cells,
activated macrophages, and aggregated platelets, it is easy to
speculate that this factor accumulates at local sites of renal
injury. Furthermore, the overexpression of PDGF-B chain
and its cognate receptor PDGFRb has been reported in many
glomerular diseases, and their levels are correlated with the
disease severity.1,3 The involvement of the PDGF system has
been shown in both human disease and experimental models,
wherein PDGF enhances the progression of glomerular
diseases by stimulating the proliferation of mesangial cells
and the synthesis of extracellular matrix proteins and
transforming growth factor-b.1,4
Selective inhibition of PDGF action is therefore consid-
ered a major target for specific and effective therapy for
glomerular diseases. Imatinib mesylate, a potent inhibitor of
PDGF receptor tyrosine kinase (RTK), has ameliorated the
pathological findings of experimental mesangial proliferative
glomerulonephritis in rats.5 In addition, specific antagonism
of PDGF-B chain6,7 and PDGF-DD8 with neutralizing
antibodies has reduced mesangial cell proliferation and
extracellular matrix protein accumulation in an experimental
nephritis model. However, therapeutic effects of PDGF signal
inhibition are not satisfactory in animal models, and do not
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fulfill the requirement for clinical application. To establish
effective molecular-targeted therapy for progressive glomer-
ular diseases, further investigation is required regarding the
signal transduction pathways downstream of PDGFR in
mesangial cells. In particular, we should consider the
involvement of other growth factors and RTKs.
In this study, we attempted to elucidate the mechanisms of
human mesangial cells (HMCs) proliferation and survival by
focusing on RTK-mediated signal transduction. This study
unveiled an additional player in HMC proliferation and
survival, RON (recepteur d’origine nantais), which is a
heterodimeric RTK composed of a 40-kDa a chain and a
150-kDa b chain.9 The a chain (RONa) is extracellular and
serves as a binding platform for macrophage-stimulating protein
(MSP), whereas the b chain (RONb) traverses cell membrane
and transduces signals through tyrosine kinase domains. We
obtained evidence suggesting that RON is a relevant target of
therapeutic intervention for human glomerular diseases.
RESULTS
RONb is persistently activated during the steady-state
growth of human mesangial cells
In an initial step to clarify RTK-mediated signal transduction,
which is critical for HMC proliferation, we took advantage of
a human phospho-RTK array, which enables us to analyze the
phosphorylation states of 42 well-characterized RTKs simul-
taneously and quantitatively. For this assay, we prepared
protein samples from normal primary HMCs in three
different cell cycle conditions: quiescence; cells were cultured
in the absence of fetal calf serum (FCS) for 24 h, cell cycle
entry; cells were stimulated with FCS for 15 min after 24 h of
serum starvation, and steady-state growth; cells were cultured
in complete medium without starvation. The cell cycle status
in each condition was verified by bromodeoxyuridine (BrdU)
incorporation and DNA histogram analysis by flow cytome-
try (data not shown). As shown in Figure 1a, all 42 RTKs
showed almost negligible levels of tyrosine phosphorylation
in quiescent HMCs. The phosphorylation of PDGFRb was
readily induced at the time of cell cycle entry, consistent with
the earlier notion that PDGF acts as a principal growth factor
for HMCs. However, our assay revealed that RONb was also
phosphorylated at an equivalent level with PDGFRb after
mitogenic stimulation. More importantly, RONb phosphor-
ylation persisted during steady-state growth of HMCs,
whereas the phosphorylation of PDGFRb was significantly
attenuated (Figure 1a). We confirmed the results of phospho-
RTK blots with immunoblotting using antibodies different
from those placed on the array (Figure 1b). It is of note
that the expression of total RONb and its heterodimeric
partner RONa was stable during mesangial cell proliferation
(Figure 1b).
MSP fails to promote cell cycle entry and RONb
phosphorylation in HMCs
Given that RONb was phosphorylated in response to FCS in
HMCs, we evaluated whether MSP, a bona fide ligand for
RON, stimulated the growth of HMC. To this end, we
stimulated HMCs with optimal concentrations of FCS
(10%), PDGF-BB (10 ng/ml) and MSP (100 ng/ml) after
24 h of serum starvation, and measured the cell growth using
a BrdU incorporation assay after 24 h. Unexpectedly, MSP
failed to promote the cell cycle entry of HMC, whereas FCS
and PDGF-BB significantly increased BrdU incorporation
(Figure 2a). MSP did not affect the growth of HMCs at
different concentrations (1–1000 ng/ml) (data not shown).
The activity of MSP was verified by activation of MSP-
sensitive breast cancer cell line MDA-MB-453 (data not
shown).
After 15 min of stimulation with FCS and MSP, we
prepared whole cell lysates from HMCs, and subjected them
to immunoblot analysis for phosphorylation of RONb. In
line with the inability to induce cell proliferation, MSP did
not phosphorylate RONb (Figure 2b). In contrast, RONb was
readily phosphorylated in FCS-stimulated HMCs, indicating
that FCS contains a factor other than MSP, which is
responsible for RONb phosphorylation.
PDGF induces RONb phosphorylation through PDGFR in
HMCs
To determine the factor(s) responsible for RONb phosphor-
ylation, we first examined whether PDGF-BB could phos-
phorylate RONb because PDGF-BB is the major growth
factor for HMCs. To test this possibility, we compared the
kinetics of tyrosine phosphorylation of RONb with that of
PDGFRb induced by highly purified recombinant PDGF-BB
in HMCs. As described earlier,1,2 the phosphorylation of
PDGFRb was readily observed after 10 min, peaked at 20 min,
and declined 50 min after the addition of PDGF at an
optimal concentration (Figure 3a). As we speculated, PDGF-
BB induced the phosphorylation of RONb with different
kinetics to that of PDGFRb: It appeared later and was
sustained longer than the phosphorylation of PDGFRb.
This is consistent with the pattern obtained in phospho-RTK
assays.
Next, we investigated whether PDGF-induced phosphory-
lation of RONb was a downstream event of the PDGF
receptor signaling pathways. For this purpose, we pretreated
serum-starved HMCs with imatinib mesylate, a potent
inhibitor of PDGFR tyrosine kinase,5 stimulated with
PDGF-BB for 30 min, and analyzed the phosphorylation of
RONb. As shown in Figure 3b, imatinib mesylate inhibited
PDGF-mediated phosphorylation of RONb concomitantly
with a decrease in the phosphorylated species of PDGFRb in
a dose-dependent manner.
Physical interactions between PDGFRb and RONb in HMCs
We hypothesized that PDGF-induced phosphorylation of
RONb was mediated through ligand-independent activation
of RONb because it has been reported that interleukin-3 and
epidermal growth factor (EGF) transactivate RONb through
interactions with their canonical receptors.10 To confirm this
hypothesis, we first examined the association of RONb and
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Figure 1 | Persistent phosphorylation of RONb during steady-state growth of HMCs. (a) (Upper panel) HMCs were grown to 70% confluence on
100 mm-diameter tissue culture dishes. After being serum starved for 24 h, cells were stimulated with 10% FCS, and harvested before (quiescence)
and after (cell cycle entry) 15 min. Cells cultured without starvation (steady-state growth) were also harvested for the isolation of whole cell lysates.
Phospho-RTK arrays were hybridized with 500mg protein of whole cell lysates, followed by incubation with an anti-phosphotyrosine detection
antibody. The locations of RTKs and internal controls are indicated in Table S1. (Lower panel) The signal intensities of phosphorylated RONb and
PDGFRb were quantified and normalized to the average values of the intensities of anti-phosphotyrosine antibodies placed on A1-2, A23-24, F1-2,
and F23-24 (positive controls). The means±s.d. (bars) of two independent experiments are shown. (b) Expressions of phosphorylated PDGFRb
(p-PDGFRb), total PDGFRb (PDGFRb), phosphorylated RONb (p-RONb), total RONb (RONb), and total RONa (RONa) were examined by immunoblotting
in quiescence (Q), at the time of cell cycle entry (C), and during steady-state growth (S) of HMCs. The membranes were reprobed with b-actin as a
loading control (some membranes are overlapped). Arrowheads indicate cross-reactive bands inevitably detected by some antibodies as described in
manufacturers’ datasheets. Nonetheless, the assignment of each band was based on the sizes and signal intensities. The signal intensities of each band
were quantified and normalized to those of corresponding b-actin (setting at 1.0). The means±s.d. (bars) of three independent experiments are
shown. Statistical differences were determined by one-way ANOVA with Scheffe multiple comparison test (asterisks denote Po0.01).
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PDGFRb using immunoprecipitation–immunoblot assays. As
shown in Figure 4a, the physical interaction between RONb
and PDGFRb was readily detected in quiescent HMCs, and
was apparently enhanced during steady-state growth. We
further showed the intracellular association of two molecules
using immunocytochemistry under confocal laser micro-
scopy. Figure 4b showed that RONb and PDGFRb were co-
localized on the cell surface, and the former was also detected
in the nucleus of HMCs. Furthermore, we evaluated the
localization of the phosphorylated form of RONb, and found
that RONb was predominantly present in the nucleus of
HMCs on phosphorylation (Figure 4c, left panel). This
unexpected finding was confirmed by immunoblotting of
enriched nuclear fractions from serum-stimulated HMCs
using an antibody specifically recognizing the phosphorylated
form of RONb (Figure 4c, right panel). These results suggest
that RONb translocates into the nucleus when activated by
phosphorylation. The biological significance and underlying
mechanism of this phenomenon remain to be determined,
but a similar observation has been reported in KDR, a type 2
receptor of vascular endothelial cell growth factor.11
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Figure 2 | MSP does not stimulate cell proliferation or induce
RONb phosphorylation in HMCs. (a) Serum-starved HMCs were
exposed to 10% FCS, 10 ng/ml PDGF-BB, and 100 ng/ml MSP for
24 h, and cell growth was monitored with BrdU incorporation.
BrdU incorporation is shown as a percentage of the value
obtained with untreated cells (control). Results are expressed as
the means±s.d. (bars) of three independent experiments. (b)
Serum-starved HMCs were exposed to none (control), 100 ng/ml
MSP, and 10% FCS for 15 min, and subjected to immunoblot
analysis for the expression of phosphorylated RONb (p-RONb).
The membrane was reblotted with an antibody to b-actin as a
loading control. The signal intensities of each band were
quantified and normalized to those of corresponding b-actin
(setting at 1.0). The means±s.d. (bars) of three independent
experiments are shown. Statistical differences were determined
by one-way ANOVA with Scheffe multiple comparison test
(asterisks denote Po0.01).
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Figure 3 | PDGF induces RONb phosphorylation through
PDGFR in HMCs. (a) Serum-starved HMCs were cultured with
10 ng/ml PDGF-BB, and subjected to immunoblot analysis for the
expression of phosphorylated PDGFRb (p-PDGFRb) and
phosphorylated RONb (p-RONb at the indicated time points). The
membrane was reblotted with an antibody to b-actin as a loading
control. (b) Serum-starved HMCs were exposed to 10 ng/ml
PDGF-BB in the absence or presence of imatinib mesylate at 10mM
or 100 mM. After 15 min, total protein lysates were isolated for the
detection of phosphorylated PDGFRb (p-PDGFRb), total PDGFRb
(PDGFRb), phosphorylated RONb (p-RONb), total RONb (RONb),
and b-actin (loading control). The signal intensities of each band
were quantified and normalized to those of corresponding b-actin
(setting at 1.0). The means±s.d. (bars) of three independent
experiments are shown. Statistical differences were determined
by one-way ANOVA with Scheffe multiple comparison test
(asterisks denote Po0.01).
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Figure 4 | Physical interactions between PDGFRb and RONb in HMCs. (a) Intracellular association of PDGFRb and RONb was detected by
immunoprecipitation–immunoblot assays. (Left panel) RONb-containing protein complex was immunoprecipitated from HMCs during
quiescence (Q) and steady-state growth (S), and separated on SDS-PAGE, followed by immunoblotting with anti-PDGFRb and anti-RONb
antibodies. IgH indicates a heavy chain of immunoglobulin. (Right panel) The same experiment was performed in reverse order. (b) HMCs
were cultured on glass slides, and fixed in 4% paraformaldehyde in PBS. In situ detection of PDGFRb (green) and RONb (red) was carried out
with confocal laser microscopy. (c) (Left panel) In situ detection of phosphorylated RONb (red) and phosphorylated PDGFRb (green) was
carried out with confocal laser microscopy. (Right panel) The fractions enriched for cytosol, membrane, and nucleus were prepared from
HMCs and subjected to immunoblot analysis for RONb, phosphorylated RONb, histone H1 (nuclear marker), and GAPDH (cytosolic marker).
We calculated the relative intensities of each band with the strongest signal setting at 1.0, and show the means±s.d. (bars) of three
independent experiments. Statistical differences were determined by one-way ANOVA with Scheffe multiple comparison test (asterisks
denote Po0.01).
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PDGF-induced transactivation of RONb is specific for
mesangial cells
The above results strongly suggested that RONb could be
activated in a ligand-independent manner through cross-talk
with PDGFRb in HMCs. The next question was whether this
PDGF–PDGFRb–RONb signaling pathway is specific to
HMCs or is also active in other cell types. To address this
question, we used normal human epidermal keratinocytes
expressing both PDGFRb and RONb. Normal human
epidermal keratinocytes were serum-starved for 24 h, exposed
to purified human recombinant PDGF-BB at an optimal
concentration, and harvested for immunoblotting at the
indicated time points (Figure 5). As is clearly shown, PDGF-
BB failed to induce phosphorylation of RONb in normal
human epidermal keratinocytes. In addition, we carried out
the same experiments with peripheral blood-derived adher-
ent monocytes, which express both PDGFRb and RONb.
Phosphorylation of RONb was not observed in adherent
monocytes cultured with PDGF (data not shown), suggesting
that PDGF-mediated transactivation of RONb is specific for
mesangial cells within the renal system.
Persistent phosphorylation of RONb during steady-state
growth is due to relatively early dissociation from SHP2 and
PP1 phosphatases
To clarify the mechanism by which RONb phosphorylation
persisted during steady-state growth of HMCs, we investi-
gated the kinetic difference in the affinity with phosphatases
between PDGFRb and RONb. For this purpose, we first
screened for the expression of various phosphatases in HMCs
by immunoblotting. HMCs expressed SHP-2 and PP1, but
not SHP-1, SHIP, and SIRP1 (data not shown). We therefore
examined the association of SHP-2 and PP1 with either
PDGFRb or RONb using immunoprecipitation–immunoblot
assays at the time of cell cycle entry and during steady-state
growth. The association of PDGFRb with SHP-2 and PP1 was
detectable at the time of cell cycle entry, and persisted during
steady-state growth of HMCs (Figure 6, left panel). This may
underlie the transient nature of PDGF-induced phosphoryla-
tion of PDGFRb. In contrast, the association of RONb with
SHP-2 and PP1 almost disappeared during steady-state
growth (Figure 6, right panel). The relatively lower affinity
to phosphatases contributes, at least in part, to the sustained
phosphorylation of RONb during steady-state growth of
HMCs.
RONb mediates anti-apoptotic function in human mesangial
cells
Sustained phosphorylation of RONb suggests its additional
role(s) during the steady growth phase of HMCs. To clarify
this point, we examined the biological consequence of the
knockdown of RONb by the aid of siRNA. HMCs were
transfected with either siRNA targeting the RON gene or
scrambled control, and assessed for cell growth and death
using BrdU incorporation and propidium iodide staining,
respectively, after 48 h. As shown in Figure 7a, siRNA-
mediated targeting of RON resulted in a significant increase
in the proportion of apoptotic cells, but not cells undergoing
DNA synthesis. These results suggest that RON contributes to
the sustained growth of HMCs primarily by suppressing
apoptosis, but not directing cell proliferation.
Next, we investigated the mechanisms by which RON
suppresses apoptosis in HMCs. Immunoblot analysis
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revealed that an increase in the amount of phosphorylated
SAPK/JNK coincided with the downregulation of RONb in
HMCs treated with siRNA against RON (Figure 7b). In
addition, there was a decrease in the abundance of Akt
phosphorylated at threonine-308 and Bad phosphorylated at
serine-136 (Figure 7b). It has been shown that SAPK/JNK
promotes apoptosis on phosphorylation12 and the phosphor-
ylation of Akt and Bad at threonine-308 and serine-136,
respectively, favors cell survival.13–15 Therefore, it is plausible
that RON suppresses apoptosis of HMCs by modulating the
activities of these molecules.
RONb is phosphorylated in glomerular lesions of human
mesangial proliferative glomerulonephritis
Finally, we attempted to clarify the biological significance of
RONb phosphorylation in vivo. For this purpose, we
examined the phosphorylation status of RONb in glomerular
lesions of mesangial IgA nephropathy, a prototype mesangial
proliferative disease, using immunohistochemistry. As con-
trols, we stained PDGFRb in the same samples and
performed the same experiments using biopsy specimens
from patients with minimal change nephrotic syndrome
(MCNS), which is not associated with mesangial cell
proliferation. As shown in Figure 8c, a marked increase in
PDGFRb expression was observed in samples from patients
with IgA nephropathy, but not in those from patients with
MCNS, consistent with the role of the PDGF/PDGFR system
in the proliferation of HMCs.1–3 It is of note that the
expression of phosphorylated RONb was also upregulated in
glomerular lesions of IgA nephropathy compared with those
of MCNS (Figure 8d). Quantification of the positivity of
phosphorylated RONb revealed that the difference between
IgA nephropathy (56.5±2.1%) and MCNS (37.6±6.8%) was
statistically significant (Po0.01) (Figure 8e). These results
suggest that RONb activation is implicated in the develop-
ment of mesangial proliferative glomerulonephritis, and is an
additional target of therapeutic intervention.
DISCUSSION
Although the importance of PDGF in the proliferation of
HMCs has been established, targeted inhibition of the PDGF/
PDGFR system has shown only limited efficacy against
mesangial proliferative diseases. This implies that additional
signal-transducing molecules are involved in the proliferation
of HMCs. In this study, we found that RON is activated
during the steady-state growth of HMCs, in which PDGFR is
inactivated by dephosphorylation, and suppresses apoptosis
through the SAPK/JNK and Akt pathways. The activation of
RON is ligand-independent and is mediated through
transactivation from PDGFR after engagement with PDGF.
We also showed that RONb is phosphorylated in glomerular
lesions of patients with IgA nephropathy. These results
suggest that RON is involved in mesangial cell proliferation
under both physiological and pathological conditions, and is
a relevant target of therapeutic intervention for human
glomerular diseases.
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Figure 7 | RON regulates apoptosis, but not cell growth in
HMCs. (a) HMCs were transfected with 50 nM siRNA targeting the
RON gene (RON siRNA) or non-targeting siRNA (control siRNA).
After 48 h, the cells were subjected to BrdU incorporation (left
panel) and Annexin-V assay (right panel). BrdU incorporation is
shown as a percentage of the value obtained with non-targeting
siRNA. The results are expressed as the means±s.d. (bar) of three
independent experiments. Statistical analysis was performed with
Student’s t-test (asterisks denote Po0.01). (b) HMCs were
transfected with 50 nM siRNA targeting the RON gene (RON siRNA)
or non-targeting siRNA (Control siRNA). After 48 h, total protein
lysates were prepared from the transfectants and untreated HMCs
(no siRNA) and analyzed by immunoblotting using antibodies
against RONb, phosphorylated-SAPK/JNK, phosphorylated-Akt,
and phosphorylated-Bad. The same membrane was reblotted
with an antibody to b-actin for loading control. The signal
intensities of each band were quantified and normalized to those
of corresponding b-actin (setting at 1.0). The means±s.d. (bars) of
three independent experiments are shown. Statistical differences
were determined by one-way ANOVA with Scheffe multiple
comparison test (asterisks denote Po0.01).
Kidney International (2009) 75, 1173–1183 1179
T Kobayashi et al.: Transactivation of RON via PDGFRb in mesangial cells o r i g i n a l a r t i c l e
RON belongs to Met family RTKs. It was originally
isolated from a human keratinocyte cDNA library,16 and the
murine homolog, also called STK (stem cell-derived tyrosine
kinase), was cloned from hematopoietic stem cells.17 RON is
mainly expressed in resident peritoneal macrophages,18
adherent monocytes,19 osteoclasts,20 mesangial cells,21 and
epithelial tissues in the skin, colon, breast, lung and
kidney.22–25 In the kidney, RON is expressed in tubular
epithelium cells, mesangial cells, and glomerular-infiltrating
monocytes in experimental glomerulonephritis model.26
Recent studies have shown that RON expression is frequently
altered in several primary human cancers, including those of
breast, colon, and ovary.27–29 In addition, truncation of RON
has been found in primary tumors of the gastrointestinal
tract.30 Although these findings point to a role of RON in the
regulation of physiological and pathological cell growth, the
precise functions of RON in HMCs remain elusive.
MSP, a member of the plasminogen-related growth factor
family, is known as a sole ligand for RON.31 The MSP/RON
system elicits diverse biological effects in a number of cell
types. These include the inhibition of inducible nitric oxide
synthase by macrophages,32 contribution to wound healing
and liver regeneration,33 proliferation and migration of
keratinocytes,34 and a potential role in bone resorption.20
The studies in vivo suggest that RON regulates inflammatory
responses in the skin,34 liver,35 and lung.36,37
In this study, MSP failed to phosphorylate RONb, but
instead PDGF-BB induced the phosphorylation of RONb in
HMCs. The reason for the insensitivity of HMCs to MSP is at
present unknown, but evidence from gene-targeted mice
provides a clue. Complete disruption of the RON gene leads
to the death of mouse embryos in the early stage, suggesting
that RON is absolutely required for embryonic develop-
ment.38 Unlike with RON deficiency, MSP knockout mice are
not lethal and do not show any visible phenotypic changes,
indicating that MSP is dispensable for cell growth and basal
cellular functions.33 The striking difference in the conse-
quences of RON and MSP deficiencies raises the possibility
that additional ligand(s) for RON and/or alternate mechan-
ism(s) of RON activation exist. Our findings suggest that
PDGF may compensate for the loss of MSP by transactivating
RON in MSP knockout mice.
PDGFR is not an exclusive partner of RON. Recent studies
have shown that RON is spatially and functionally associated
with other transmembrane molecules including adhesion
receptors (integrins and cadherins) and cytokine and growth
factor receptors (IL-3 receptor, erythropoietin receptor, EGF
receptor, and Met).10,39–41 The interaction between RON and
IL-3 receptor is known to be unidirectional: MSP induces the
phosphorylation of both RON and IL-3 receptor, whereas IL-
3 does not phosphorylate RON.39 In contrast, cross talk of
RON with either Met or EGF receptor is bidirectional.40,41 As
shown in this study, the interaction between RON and
PDGFR is also unidirectional. PDGF-mediated transactiva-
tion of RON seems to be unique to HMCs in the renal
system; it was not observed in activated monocytes, and
tubular epithelial cells express RON, but not PDGFR (data
not shown).
As a mechanism of the persistent phosphorylation of RON
during sustained growth of HMCs, we propose a difference in
the affinity to phosphatases, SHP-2 and PP1, between RON
and PDGFR. Activities of RTKs are regulated by protein
tyrosine phosphatases in many ways.42 SHP-2 has been
described as a regulator of multiple RTK signaling path-
ways.43,44 In addition, RTKs also contain several serine and
threonine residues. There is increasing evidence that serine/
threonine phosphorylation also plays a relevant role in
modulating RTK functions.45 It has been shown that PP1 is
involved in serine dephosphorylation of RON.46
Finally, we have shown for the first time the increased
phosphorylation of RON in glomerular lesions of patients
with IgA nephropathy, a prototype mesangial proliferative
nephritis. This finding may be a clue to understanding the
mechanisms of chronic mesangial proliferation more pre-
cisely, and provides a rational basis for the development of
better treatment strategies for human glomerular diseases.
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Figure 8 | Expression of phosphorylated RON in the
glomerular lesions of mesangial proliferative diseases. Renal
biopsy specimens from patients with minimal change nephrotic
syndrome (MCNS) (a and b) and IgA nephropathy (c and d) were
stained for the detection of PDGFRb (a and c) and phosphorylated
RONb (b and d). Representative photographs are shown (original
magnification, 400). (e) The proportions of phosphorylated
RON-positive cells in glomerular cells were quantified in 6 and 24
samples from MCNS and IgA nephropathy, respectively (asterisk
denotes Po0.01 by Student’s t-test). Data shown are the
means±s.d. (bars) of the percentages of pRONb-positive cells in
each glomerulus (10 glomeruli were examined in each case).
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MATERIALS AND METHODS
Cells and cell culture
Normal primary human mesangial cells were purchased from
Cambrex BioScience (Walkersville, MD, USA). Cells were main-
tained in RPMI1640 medium (Sigma-Aldrich Co., St Louis, MO,
USA) supplemented with 10% FCS and 10 mg/ml insulin, 5.5mg/ml
transferrin, and 6.7 ng/ml sodium selenite (Life Technology,
Carlsberg, CA, USA). Normal human epidermal keratinocytes were
purchased from Kurabo (Osaka, Japan). Cells were grown in
Keratinocyte-SFM medium (Invitrogen, NY, USA) supplemented
with 30 mg/ml bovine pituitary extract and 0.2 ng/ml recombinant
EGF. Cells used in the present experiments were from four to eight
passages.
Cell proliferation assay
HMCs were growth-arrested for 24 h in serum-free RPMI1640
medium, and incubated with either 10 ng/ml PDGF-BB (R&D
Systems, Minneapolis, MN, USA), 100 ng/ml MSP (R&D Systems),
or 10% FCS for 24 h. DNA synthesis was monitored for the final 6 h
using a BrdU incorporation assay kit (Roche Diagnostics, Man-
nheim, Germany).
Transfection of siRNA
Transfection of siRNA was carried out using a Dharmafect
transfection reagent (GE Healthcare UK Ltd, Buckinghamshire,
England) according to the manufacturer’s instructions. HMCs were
grown in six-well dishes, and transfected with either siRNA against
RON (macrophage stimulating 1 receptor (MST1R) ON-TARGET
plus SMARTpool) or control siRNA (siCONTROL Non-targeting
siRNA pool) (Dharmacon, Inc., Lafayette, CO, USA) at 50 nM for
24 h. The sequences of RON and control siRNAs are 50-UAAAU-
CUAUAGGUCUGCAGUU, 50-UCACACUCAAACUCCUCUAUU,
50-UAUGACAUUCACCAUCUACUU, and 50-CUAUCGGAGAAGG
AUGCUCUU; and 50-UGGUUUACAUGUCGACUAA, 50-UGGUU
UACAUGUUUUCUGA, 50-UGGUUUACAUGUUUUCCUA, and
50-UGGUUUACAUGUUGUGUGA, respectively.
Flow cytometry
Cell cycle profile was determined by staining DNA with propidium
iodide, and the size of the sub-G1 fraction was calculated as a
percentage with the ModFitLT 2.0 program (Verity Software,
Topsham, ME, USA). For the detection of apoptosis, cells were
stained with PE-conjugated annexin-V (Biovision, Mountain View,
CA, USA).
Cell fractionation
Cells were fractionated into cytosol, membranes, nuclei, and
cytoskeleton using a Subcellular ProteoExtract kit (EMD Chemicals,
San Diego, CA, USA) according to the manufacturer’s directions.
RTK array analysis
We used a human Phospho-RTK Array kit (R&D Systems) to
simultaneously detect relative tyrosine phosphorylation levels of 42
different RTKs. Whole cell lysates were prepared in chilled cell lysis
buffer (50 mM Tris-HCL, pH 8.0, 120 mM NaCl2, 0.5% Nonidet P-40,
100 mM sodium fluoride, and 200 mM sodium orthovanadate). Array
membranes were blocked and hybridized with 500 mg of protein
samples overnight at 41C, followed by incubation with an anti-
phosphotyrosine antibody conjugated with horseradish peroxidase
for 2 h at room temperature. After being washed, membranes were
developed with ECL Western blotting detection reagent (GE
Healthcare, UK).
Immunoblotting
Immunoblotting was carried out according to the standard method.
The following primary antibodies were used: anti-human MSPR/
Ron beta (R&D Systems), anti-RON alfa (BD Transduction
Laboratories, San Jose, CA, USA), anti-phosphorylated RON
(Tyr1238/Tyr1239) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-PDGFRb (Cell Signaling Technology, Danvers, MA,
USA), anti-phosphorylated PDGFRb (Tyr751) (Cell Signaling
Technology), anti-phosphorylated SAPK/JNK (Thr183/Tyr185)
(Cell Signaling Technology), anti-phosphorylated Akt (Thr308)
(Cell Signaling Technology), anti-phosphorylated Bad (Ser136) (Cell
Signaling Technology), anti-histone H1 (Santa Cruz Biotechnology),
anti-GAPDH (Santa Cruz Biotechnology), and anti-b-actin (C4;
ICN Biomedicals, Aurora, OH, USA).
Immunoprecipitation–immunoblotting assays
After being precleared with protein A-sepharose, whole cell lysates
(500 mg protein) were incubated with 2 mg of either anti-RON
polyclonal antibody (ABGENT, San Diego, CA, USA), anti-PDGFRb
polyclonal antibody (Cell Signaling Technology), or rabbit IgG in
200 ml of cell lysis buffer. After brief centrifugation, the supernatants
were rocked overnight at 41C in the presence of protein A-sepharose
beads. Immune complexes were collected on the beads, washed three
times in cell lysis buffer, and applied to 10% SDS-PAGE, followed by
immunoblotting with either anti-RON, anti-PDGFRb, anti-SHP2
(BD Biosciences, Franklin Lakes, NJ, USA), or anti-PP1 (Santa Cruz
Biotechnology) monoclonal antibody.
Confocal laser microscopy
Cells were cultured on Shandon cytoslides for 24 h (Thermo
Scientifics, Pittsburgh, PA, USA) and fixed in 4% paraformaldehyde
in phosphate-buffered saline. RONb was stained with anti-MST1R/
RON polyclonal antibody (MBL, Japan) and a goat antibody to
rabbit immunoglobulin conjugated with Alexa 488 (Molecular
Probes, Eugene, OR, USA). PDGFRb was stained with anti-PDGFRb
monoclonal antibody (Cell Signaling Technology) and a donkey
antibody to mouse immunoglobulin conjugated with Cy3
(Amersham Biosciences, Buckinghamshire, England). Phosphory-
lated RONb was stained with anti-phosphorylated RONb (Tyr1238/
1239) and a goat antibody to rabbit immunoglobulin conjugated
with Alexa 488. Phosphorylated PDGFRb was stained with anti-
phosphorylated PDGFRb and a donkey antibody to mouse
immunoglobulin conjugated with Cy3. Confocal microscopic
analysis was performed as described earlier.47
Immunohistochemistry
We examined renal biopsy specimens from 30 patients with renal
diseases, including 24 patients with IgA nephropathy (age: 16–65,
sex: male/female¼ 11/13) and six patients with MCNS (age: 19–70,
sex: male/female¼ 3/3), admitted to Jichi Medical University
Hospital. The ethics committee of Jichi Medical University approved
this study, and all patients gave written informed consent before
entry into the study. The expressions of phosphorylated RONb and
PDGFRb were evaluated by immunohistochemistry. Formalin-fixed
paraffin-embedded sections (3mm) were deparaffinized in xylene,
rehydrated in graded ethanol, and subjected to antigen retrieval
procedure in 10 mmol/l of boiling citrate buffer solution (pH 6.0).
Non-specific protein staining was blocked by preincubation for
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10 min with normal swine serum. Tissue sections were incubated
overnight at 41C with either anti-phosphorylated RONb antibody
(Santa Cruz Biotechnology) or anti-PDGFRb antibody (Cell
Signaling Technology) at final dilutions of 1:200 and 1:50,
respectively. After being washed with PBS, tissue sections were
treated with the Envision Plus polyclonal system (Dako, Santa
Barbara, CA, USA). Samples were developed with liquid diamino-
benzidine and counterstained with Mayer’s hematoxylin.
Statistical analysis
The results of immunoblot experiments including phospho-RTK
assays were quantified using the Scion Image software (Scion
Corporation, Frederick, MD, USA). Statistical differences were
determined by either Student’s t-test or one-way analysis of variance
(ANOVA) with Scheffe multiple comparison test on the Stat View
program (SAS Institute, Cary, NC, USA) with Po0.01 being
considered significant.
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